Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
New Approaches in Leukemia
share announcement

New Approaches in Leukemia

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 902

Special Issue Editors

Dr. Harinder Gill

E-Mail Website
Guest Editor
Clinical Associate Professor, Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong, Hong Kong, Hong Kong
Interests: acute myeloid leukemia (AML); acute promyelocytic leukemia (APL); myelodysplastic neoplasm (MDS); myeloproliferative neoplasm (MPN)
Dr. Naveen Pemmaraju

E-Mail Website
Guest Editor
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Interests: myeloid malignancies; blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Dr. Hsin-An Hou

E-Mail Website
Guest Editor
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Interests: acute myeloid leukemia; myelodysplastic neoplasm (MDS); myeloproliferative neoplasm (MPN)
Dr. Melissa Gaik Ming Ooi

E-Mail Website
Guest Editor
Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
Interests: plasma cell dyscrasias; acute leukemia; myelodysplastic neoplasm (MDS)

Special Issue Information

Dear Colleagues,

The current era in personalized and genomic medicine has seen significant advances in the diagnosis, risk stratification and management of acute and chronic leukemias.

We are pleased to invite you to contribute to this Special Issue entitled “New Approaches in Leukemia”.

This Special Issue aims to explore the latest advances and understanding in the classification, pathogenesis and treatment of acute myeloid leukemia, acute promyelocytic leukemia, acute lymphoblastic leukemia, blastic plasmacytoid dendritic cell neoplasm (BPDCN), myelodysplastic neoplasm (MDS), myeloproliferative neoplasm (MPN), chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL).

Original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  1. Disease classification;
  2. Prognostic factors;
  3. Pathogenesis;
  4. Measurable residual disease (MRD);
  5. Biomarkers of treatment response;
  6. Treatment.

We look forward to receiving your contributions.

Dr. Harinder Gill
Dr. Naveen Pemmaraju
Dr. Hsin-An Hou
Dr. Melissa Gaik Ming Ooi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • acute myeloid leukemia
  • acute promyelocytic leukemia
  • acute lymphoblastic leukemia
  • blastic plasmacytoid dendritic cell neoplasm (BPDCN)
  • myelodysplastic neoplasm (MDS)
  • myeloproliferative neoplasm (MPN)
  • chronic myeloid leukemia (CML)
  • chronic lymphocytic leukemia (CLL)

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 2176 KiB  
Article
Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic Blasts
by Samuel J. Holzmayer, Joseph Kauer, Jonas Mauermann, Tobias Roider and Melanie Märklin
Cancers 2024, 16(7), 1288; https://doi.org/10.3390/cancers16071288 - 26 Mar 2024
Viewed by 705
Abstract
B cell acute lymphoblastic leukemia (B-ALL) is characterized by an accumulation of malignant precursor cells. Treatment consists of multiagent chemotherapy followed by allogeneic stem cell transplantation in high-risk patients. In addition, patients bearing the BCR-ABL1 fusion gene receive concomitant tyrosine kinase inhibitor (TKI) [...] Read more.
B cell acute lymphoblastic leukemia (B-ALL) is characterized by an accumulation of malignant precursor cells. Treatment consists of multiagent chemotherapy followed by allogeneic stem cell transplantation in high-risk patients. In addition, patients bearing the BCR-ABL1 fusion gene receive concomitant tyrosine kinase inhibitor (TKI) therapy. On the other hand, monoclonal antibody therapy is increasingly used in both clinical trials and real-world settings. The introduction of rituximab has improved the outcomes in CD20 positive cases. Other monoclonal antibodies, such as tafasitamab (anti-CD19), obinutuzumab (anti-CD20) and epratuzumab (anti-CD22) have been tested in trials (NCT05366218, NCT04920968, NCT00098839). The efficacy of monoclonal antibodies is based, at least in part, on their ability to induce antibody-dependent cellular cytotoxicity (ADCC). Combination treatments, e.g., chemotherapy and TKI, should therefore be screened for potential interference with ADCC. Here, we report on in vitro data using BCR-ABL1 positive and negative B-ALL cell lines treated with rituximab and TKI. NK cell activation, proliferation, degranulation, cytokine release and tumor cell lysis were analyzed. In contrast to ATP site inhibitors such as dasatinib and ponatinib, the novel first-in-class selective allosteric ABL myristoyl pocket (STAMP) inhibitor asciminib did not significantly impact ADCC in our settings. Our results suggest that asciminib should be considered in clinical trials. Full article
(This article belongs to the Special Issue New Approaches in Leukemia)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop